Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes
- 4 November 2003
- journal article
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 3 (6) , 335-342
- https://doi.org/10.1038/sj.tpj.6500210
Abstract
The present study investigated the effect of cytochrome P450 2C9 (CYP2C9) genetic polymorphism on the biotransformation of valproic acid (VPA) to its hepatotoxic metabolite, 4-ene-VPA, and compared that to the formation of the inactive 4-OH-VPA and 5-OH-VPA. cDNA-expressed CYP2C9*2 and CYP2C9*3 variants were less efficient than the CYP2C9*1 wild type in catalyzing the formation of these metabolites, as assessed by the ratio of Vmax and apparent Km (in vitro intrinsic clearance). The reduced efficiency by CYP2C9*2 was due to a reduced Vmax, whereas, in the case of CYP2C9*3, it was the result of increased apparent Km. The formation rates of 4-ene-VPA, 4-OH-VPA, and 5-OH-VPA in human liver microsomes were reduced by 29, 28, and 31%, respectively, in samples with one mutated CYP2C9 allele, and by 61, 73, and 58%, respectively, in samples with two mutated CYP2C9 alleles. Overall, the homozygote and heterozygote CYP2C9*2 and CYP2C9*3 genotypes may compromise hepatic VPA biotransformation.Keywords
This publication has 34 references indexed in Scilit:
- Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humansBritish Journal of Clinical Pharmacology, 2003
- Influence of Age and Cytochrome P450 2C9 Genotype on the Steady-State Disposition of Diclofenac and CelecoxibClinical Pharmacokinetics, 2003
- Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African populationBritish Journal of Clinical Pharmacology, 2001
- Pharmacogenetics of Warfarin Elimination and its Clinical ImplicationsClinical Pharmacokinetics, 2001
- Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoinBritish Journal of Clinical Pharmacology, 1999
- Cytochrome P450 Isozymes and Antiepileptic Drug InteractionsEpilepsia, 1995
- Valproic AcidDrugs, 1994
- Valproate hepatotoxicity syndrome: Hypotheses of pathogenesisInternational Journal of Clinical Pharmacy, 1992
- Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactionsChemical Research in Toxicology, 1992
- Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9Biochemical and Biophysical Research Communications, 1991